Antithrombin up-regulates AMP-activated protein kinase signalling during myocardial ischaemia/reperfusion injury

Yina Ma1; Jinli Wang1; Junjie Gao1; Hui Yang1; Yanqing Wang1; Chandrashekhara Manithody2; Ji Li1; Alireza R. Rezaie2

1Department of Pharmacology and Toxicology, State University of New York at Buffalo, New York, USA; 2Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA

Summary
Antithrombin (AT) is a protein of the serpin superfamily involved in regulation of the proteolytic activity of the serine proteases of the coagulation system. AT is known to exhibit anti-inflammatory and cardioprotective properties when it binds to heparan sulfate proteoglycans (HSPGs) on vascular cells. AMP-activated protein kinase (AMPK) plays an important cardioprotective role during myocardial ischaemia and reperfusion (I/R). To determine whether the cardioprotective signaling function of AT is mediated through the AMPK pathway, we evaluated the cardioprotective activities of wild-type AT and its two derivatives, one having high affinity and the other no affinity for heparin, in an acute I/R injury model in C57BL/6J mice in which the left anterior descending coronary artery was occluded. The serpin derivatives were given 5 minutes before reperfusion. The results showed that AT-WT can activate AMPK in both in vivo and ex vivo conditions. Blocking AMPK activity abolished the cardioprotective function of AT against I/R injury. The AT derivative having high affinity for heparin was more effective in activating AMPK and in limiting infraction, but the derivative lacking affinity for heparin was inactive in eliciting AMPK-dependent cardioprotective activity. Activation of AMPK by AT inhibited the inflammatory c-Jun N-terminal protein kinase (JNK) pathway during I/R. Further studies revealed that the AMPK activity induced by AT also modulates cardiac substrate metabolism by increasing glucose oxidation but inhibiting fatty acid oxidation during I/R. These results suggest that AT binds to HSPGs on heart tissues to invoke a cardioprotective function by triggering cardiac AMPK activation, thereby attenuating JNK inflammatory signalling pathways and modulating substrate metabolism during I/R.

Introduction

As the leading cause of death ranked by the World Health Organisation, ischaemic heart disease is caused by the reduction of the coronary blood supply to the myocardium. Treatment strategies for acute cardiac ischaemia include primary angioplasty, coronary artery bypass surgery, and the use of anticoagulant and thrombolytic drugs which are all aimed at returning blood flow back to the ischaemic area (1). Although increased blood flow aids in rapid restoration of energy, nevertheless, the irreversible cell damage caused by reperfusion is the main risk of these approaches. AMP-activated protein kinase (AMPK) plays a pivotal role in intracellular adaptation to energy stress during myocardial ischaemia (2). It has been demonstrated that the activation of cardiac AMPK is essential for accelerating ATP generation, attenuating ATP depletion and protecting the myocardium against post-ischaemic cardiac dysfunction and apoptosis (3–5). Thus, a number of studies have shown that the physiological or pharmacological activation of AMPK can decrease cardiac necrosis caused by I/R injury (6–8).

There is increasing evidence that intracellular signalling responses initiated by the natural anticoagulant pathways, antithrombin (AT) and protein C systems, play critical roles in protecting the heart against I/R injury (9–12). AT is a serine protease inhibitor of the serpin superfamily (13), which regulates the proteolytic activities of procoagulant proteases of both intrinsic and extrinsic pathways (14). However, in addition to its anticoagulant activity, AT also possesses potent anti-inflammatory activities (12). The anticoagulant activity of AT is primarily mediated through the exposed reactive centre loop of the serpin covalently modifying the active site residue of procoagulant proteases, and thereby trapping them in the form of irreversible inactive complexes incapable of interacting with their substrates (14). By contrast, the anti-in-
flammatory activity of AT has been shown to be mediated through the serpin interacting with vascular heparan sulfate proteoglycans (HSPGs) via its basic D-helix, independent of protease inhibition (9, 12, 15). The D-helix of AT is the same site to which the antithrombotic therapeutic heparins bind in order to facilitate the rapid recognition and inhibition of thrombin and other coagulation proteases by the serpin (16). It has been hypothesised that AT binds via its D-helix to vessel wall HSPGs (17), thereby inducing synthesis of prostacyclin (PGI₂) and inhibition of NF-kB in vascular endothelial cells (18). Several studies have demonstrated that the PGI₂-mediated protective function for AT can decrease liver, renal, and intestinal I/R injury (10,19–21). We also recently demonstrated that AT can elicit cardioprotective signalling responses through D-helix-dependent interaction with vascular HSPGs (18). Although the mechanism of heparin-dependent anticoagulant function of AT has been extensively studied and is relatively well understood, the HSPG-dependent cardioprotective signalling mechanism of AT during I/R injury remains unknown.

In light of a cardioprotective role for AMPK, we investigated whether AT, through interaction with vascular HSPGs, can activate AMPK to exert a cardioprotective function during I/R injury. The results demonstrate that the HSPG binding-dependent AT activation of the AMPK signalling pathway contributes to the cardioprotective function of the serpin during I/R injury.

Materials and methods

Experimental animals

Wild-type (WT) male C57BL/6j mice (12 weeks of age) and AMPK kinase dead (AMPK KD, expressing a KD α2 K45R mutation, driven in heart and skeletal muscles by the muscle creatine kinase promoter) (4), mice were used in the experiments. All animal protocols in this study were approved by the University at Buffalo-State University of New York Institutional Animal Care and Use Committee (IACUC).

In vivo regional ischaemia and infarct size measurement

Mice were anesthetised with 60 mg/kg of sodium pentobarbital (Sigma, St. Louis, MO, USA) by intraperitoneal (i.p.) injection, intubated and ventilated with a respirator (Harvard apparatus, Holliston, MA, USA). After a left lateral thoracotomy, the left anterior descending coronary artery (LAD) was occluded for 20 minutes (min) (or 60 min for myocardial necrosis measurements) using an 8-0 nylon suture and gauze pad to prevent arterial injury, and then reperfused 15 min for immunoblotting or 4 hours (h) for myocardial necrosis measurements. Vehicle (50% Glycerol/H₂O) or AT (5 or 20 µg/g, Haematologic Technologies Inc. Essex Junction, VT, USA) was administered via a tail vein injection 5 min before reperfusion. Successful occlusion of the LAD was confirmed by blanching of the left ventricle (LV) and rapid ST-segment elevation during coronary occlusion (ADInstruments, Colorado Springs, CO). The ischaemic region of the LV was freeze-clamped in liquid nitrogen for biochemical analysis.

For infarct size measurements, hearts were excised, then perfused and stained for dual colour. The non-necrotic tissue in ischaemic area [area at risk (AAR)] was stained by 2, 3, 5– triphenyltetrazolium (TTC) into red, and the infract area showed in pale (5). The LAD was then re-occluded and stained by Evans blue dye to delineate non-ischaemic region. Stained hearts were cut into 1 mm slices, photographed with a Leica microscope, and analysed with National Institutes of Health Image J software. The myocardial infarct size was calculated as the ratio of the percentage of myocardial necrosis to the ischaemic area at risk (AAR) as described (5, 22).

Ex vivo global ischaemia

Mice were heparinised (100 units i.p.) 10 min before being anesthetised. Isolated hearts were then retroperfused in the Langendorff perfusion system (Radnoti, Monrovia, CA, USA) with Krebs-Henseleit buffer (KHB) containing 7 mM glucose, 1 % bovine serum albumin (BSA), 0.4 mM sodium oleate and 10 µl/ml insulin and bubbled with 95% O₂/5% CO₂. The water jacket bath was set to 38.7 °C to keep the perfusion buffer at 37°C. For ex vivo ischaemia model, isolated hearts were subjected to 20 min perfusion, followed by 25 min global, non-flow ischaemia and then 30 min reperfusion. Hearts were freeze-clamped in liquid nitrogen for biochemical analysis. AT was given at the beginning of reperfusion.

Immunoblotting

Western blots were performed as previously described (5, 22). Heart lysates were resolved by SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). The antibodies for JNK, phosphor-JNK (Thr183/Tyr185) (p-JNK), phosphor-AMPK-Thr172 (p-AMPK), AMPKa, phosphor-Acetyl-CoA Carboxylase (p-ACC), Acetyl-CoA Carboxylase (ACC), phosphor-c-Jun (p-Jun), c-Jun, phosphor- Eukaryotic elongation factor 2 (p-eEF2), phosphor- Serine/threonine-protein kinase ULK1 (Ser555), were purchased from Cell Signalling (Danvers, MA, USA). 4 Hydroxynonenal (4 HNE) was purchased from Abcam (Cambridge, MA, USA).

Fatty acid/glucose oxidation analysis

A working heart model was used to test the cardiac substrate (fatty acid and glucose) metabolism as described (4, 23). Isolated WT or AMPK KD hearts were subjected to 20 min perfusion followed by 10 min of global ischaemia and 20 min of reperfusion. The water jacket bath was set to 38.7°C to keep the perfusion buffer at 37°C. The working heart preload was set to 38.7 °C, and the afterload was set at 80 cm H₂O. The flow rate was kept at 15 ml/min. The heart function was monitored by pressure transducer connected to aortic outflow. 9, 10-3H-oleate (50 µci/l) and 14C-glucose (20 µci/l) labelled BSA buffer perfused into the heart through...
the pulmonary vein and pumped out through the aorta. Perfusate pumped out from aorta and outflowed from coronary venous was recycled and collected every 5 min to test the radioactivity. The fatty acid level was determined by the production of $^{3}$H$_{2}$O from [9, 10]$^{3}$H-oleate. Metabolised $^{3}$H$_{2}$O was separated from [9, 10]$^{3}$H-oleate by filtering through an anion exchange resin (Bio-Rad, Hercules, CA, USA). Glucose oxidation was measured by metabolised $^{14}$CO$_{2}$ solved in buffer or gaseous (further solved in sodium hydroxide and sampled every 5 min). To separate $^{14}$CO$_{2}$ from $^{3}$H-glucone, sulfuric acid was added into perfusate samples to release $^{3}$H and $^{14}$C signals were detected to discriminate metabolic products from fatty acid and glucose, respectively.

**Isolation of cardiomyocytes**

Mice were given 100 units (i.p.) of heparin (Sagent Pharmaceuticals, Schaumburg, IL, USA) 10 min before being anesthetised with 100 mg/kg sodium pentobarbital (i.p.) (Sigma). Hearts were excised and retroperfused with the cardiomyocyte perfusion apparatus (Radnoti). The perfusion buffer which is ventilated with 95% O$_{2}$/5% CO$_{2}$ and kept at 37°C, is a Ca$^{2+}$-free Krebs–Henseleit based buffer (pH 7.3) containing 0.6 mM KH$_{2}$PO$_{4}$, 0.6 mM Na$_{2}$HPO$_{4}$, 10 mM HEPES, 14.7 mM KCl, 1.7 mM MgSO$_{4}$, 120.3 mM NaCl, 4.6 mM NaHCO$_{3}$, 30 mM taurine, 10 mM glucose, and 10 mM 2,3-butanedione monoxime. After 5 min of stabilisation,

![Figure 1: AT stimulated AMPK activation during in vivo basal and I/R and ex vivo I/R conditions. A) AT, treated for 20 min at basal condition or 5 min before reperfusion during regional ischaemia, induced phosphorylation of AMPK and phosphorylation of downstream acetyl CoA (ACC). The bar graphs (right panel) show the relative level of p-AMPK and p-ACC, respectively. B) AT-treated (2.5 µg/ml) heart ex vivo at the beginning of reperfusion during global ischaemia (25 min). AT increased the phosphorylation of AMPK, ACC and eEF2. AT treatment also inhibited the phosphorylation of JNK and its downstream protein c-Jun during ischaemia (25 min) and reperfusion (30 min) (left panel). The bar graphs (right panel) show the relative levels of p-AMPK, p-ACC, p-eEF2, p-JNK and p-c-Jun, respectively. N=5 for basal and I/R condition; n=7 for I/R/AT condition; *p< 0.05 vs Basal Vehicle or I/R Vehicle; †p< 0.05 vs I/R Vehicle.](image-url)
Ma et al. Cardioprotective function of AT

the heart was then digested with the same perfusion buffer containing 0.067 mg/ml Liberase Blendzyme 4 (Roche, Indianapolis, IN, USA) for 15 min. Hearts were then minced. Extracellular Ca$^{2+}$ was added back to the cells to reach a final concentration of 1 mM. For normoxia approach, cardiomyocytes were subjected to pharmacological drug treatment with AT or surfen (Sigma) for 20 min at 37 °C.

Permeability assay

Human umbilical vein endothelial (EA.hy926) cells (courtesy of Dr. C. Edgell from University of North Carolina at Chapel Hill, NC, USA) were used to assess the protective activity of AT in a permeability assay as described (18). Briefly, confluent endothelial cells, with or without transfection with specific siRNA for heparan sulfate 3-O-sulfotransferase-1 (HS 3-OST-1) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), were incubated with AT-WT (150 µg/ml for 3 h) before stimulating them with LPS (10 µg/ml for 4 h). Cell permeability was quantitated by the spectrophotometric measurement of the flux of Evans blue-bound albumin across the cell monolayer using a modified 2-compartment chamber model as described (18).

Statistical analysis

Data was expressed as mean ± standard error. Data was analysed with one-way ANOVA for measurement of statistical significance. For single- and multi-factorial analyses, post hoc test(s) were performed to measure the differences in individual groups of interest. A p-value of <0.05 was considered statistically significant.
Figure 3: The capacity of AT to activate AMPK correlates with its affinity for heparan sulfate proteoglycans (HSPGs). A) Hearts were subjected to 20 min ischaemia followed by 15 min reperfusion in vivo or sham operation (Basal). AT (4 µg/g) or AT derivatives (all 4 µg/g) were administered via the tail vein 5 min prior to reperfusion under ischaemia (20 min) followed by reperfusion (15 min). The hearts were homogenised for immunoblotting with p-AMPK (Thr<sup>172</sup>) or AMPK<sub>α</sub> antibodies. B) The extent of myocardial infarction (60 min ischaemia) with vehicle, wild-type AT or AT-N135Q (4 µg/g). N= 4 for basal and I/R with AT derivative; n=5 for I/R with wild-type AT. *p<0.05 vs Basal; †p<0.05 vs AT.
Results
AT stimulates AMPK phosphorylation in vivo and ex vivo

The activation of AMPK by ischaemia is known to protect the heart against I/R injury by regulating downstream metabolic pathways including glycolysis (24), glycogen synthesis (25) glucose oxidation (26), fatty acid oxidation (27), protein synthesis (28) and autophagy (3,28). In light of our recent finding that AT can elicit cardioprotective responses during I/R injury (9), we investigated whether AT-mediated AMPK signalling contributes to the cardioprotective function of the serpin. Both in vivo and ex vivo I/R
experiments were performed to test this hypothesis. The results showed that under basal conditions, the tail vein injection of AT (4 µg/g mice, 20 min before termination) activates AMPK by significantly elevating the phosphorylation of Thr172 on the α catalytic subunit of the kinase (▶Figure 1A, p<0.05). A robust AT-mediated AMPK activation was also observed when the mouse hearts were subjected to LAD occlusion for 20 min followed by 15 min of reperfusion. In this case, an optimal level of phosphorylated AMPK (p-AMPK) in the left ventricular area was observed with an AT dose of 20 µg/g mice (p<0.05 vs I/R Vehicle) (▶Figure 1A). Under both basal and I/R conditions, the phosphorylation of the downstream effector of AMPK, acetyl-CoA-carboxylase (ACC), which is involved in fatty acid oxidation (24), was also significantly increased in AT-treated groups (▶Figure 1A). Moreover, the isolated hearts were perfused in an ex vivo heart perfusion system by cannulating the aorta for basal perfusion for 25 min of global non-flow ischaemia and 30 min reperfusion. Interestingly, in addition to phosphorylation of AMPK and ACC, AT administration prior to reperfusion also significantly up-regulated the phosphorylation of eukaryotic elongation factor 2 (eEF2), a critical factor involved in the inhibition of protein synthesis (29) (▶Figure 1B). Moreover, AMPK activation by AT was associated with the inhibition of I/R-mediated phosphorylation of cardiac c-Jun and c-Jun N-terminal kinase (JNK) inflammatory pathways (▶Figure 1B, p<0.05). Taken together, results of both in vivo and ex vivo heart perfusion studies presented above indicate that AT activates the AMPK signalling pathway, thereby exerting a cardioprotective function against I/R injury.

### Inhibition of AMPK activation limits the cardioprotective activity of AT

To provide further support for the hypothesis that AMPK activation by AT leads to a cardioprotective effect during I/R injury, we pretreated mice with the AMPK inhibitor, Compound C (1 µg/g, subcutaneous injection) (30), for 30 min prior to LAD ligation-induced regional ischaemia (60 min) followed by reperfusion (4 h). The results demonstrated that pretreatment with Compound C effectively abolishes the cardioprotective effect of AT against I/R damage (▶Figure 2A and B, p<0.05). Furthermore, AT did not exhibit a significant cardioprotective effect in the AMPK kinase-dead (KD) mice during I/R (▶Figure 2A and B). These results support the hypothesis that the activation of AMPK is a major contributor to AT’s cardioprotective effect against myocardial damage during I/R.

### AT activates AMPK via D-helix dependent interaction with HSPGs

It is known that the interaction of the basic D-helix of AT with vascular HSPGs is responsible for the protective signalling activity of the serpin (16–18). To determine whether a similar mechanism is involved in the AT activation of AMPK, the activity of two AT derivatives which have different affinities for heparin was analysed in the same in vivo assay system described above. The first derivative is a D-helix mutant of AT (AT-4Mut) which is known to exhibit no affinity for heparin (32). The second derivative, in which Asn-135 of the D-helix has been replaced with a Gln (AT-N135Q), exhibits markedly higher affinity for heparin due to this residue missing a post-translationally attached carbohydrate side chain in the native serpin. This AT derivative mimics the heparin-binding properties of the β isoform of the serpin. It is known that AT circulates in plasma in two α and β isoforms (33). The β-AT isoform, which represents only 5–10% of plasma AT, lacks the carbohydrate at Asn-135 and thus binds heparin with ~5-fold higher affinity (33). Consistent with the HSPG-dependent protective signalling mechanism of the serpin, the AT-N135Q derivative activated AMPK markedly better than wild-type AT (▶Figure 3A, p<0.05). By contrast, the AT-4Mut derivative did not show any induction of AMPK activation and a synthetic therapeutic AT-binding pentasaccharide (H5), which is known to bind the D-helix of AT, abrogated the elevated AT-mediated phosphorylation of AMPK (▶Figure 3A). Further support for our hypothesis is provided by the observation that, relative to AT-WT, AT-N135Q exhibited significantly higher activity in limiting the infarct size (▶Figure 3B, p<0.05). These results clearly indicate that the D-helix dependent interaction of AT with HSPGs on cardiac tissues is responsible for increased AMPK activation during I/R injury.

### AT exerts its protective effect through interaction with 3-OS containing HSPGs

It has been hypothesized that a small subgroup of HSPGs containing a 3-O-sulfate (3-OS) moiety, which has high affinity for AT...
Ma et al. Cardioprotective function of AT (HS\(^{AT+}\)), may act as a receptor for AT to mediate the anti-inflammatory function of the serpin (15). To investigate the hypothesis that a similar mechanism may be involved in AT activating AMPK, cardiomyocytes were pretreated with the HS antagonist, surfen (31). AT-treated cardiomyocytes showed elevated AMPK activation, however, this activation was blocked after pretreating cardiomyocytes with surfen (Figure 4A, upper panel). The surfen blockade of AT-induced AMPK activation in isolated heart during the reperfusion stage further validated our hypothesis that AT, through interaction with HSPGs, stimulates AMPK activation in cardiomyocytes (Figure 4A, lower panel).

We previously demonstrated that AT exerts a potent protective effect in endothelial cells stimulated with LPS. Thus, we showed that AT inhibits LPS-enhanced permeability of endothelial cells by a concentration dependent mechanism (18). To provide further support for the hypothesis that the interaction of AT with the high
affinity HSPGs containing 3-O-sulfate (3-OS) is responsible for the protective activity of the serpin, we used siRNA for heparan sulfate 3-O-sulfotransferase-1 (HS 3-OST-1), which is the enzyme known to be responsible for the synthesis of 3-OS containing HSPGs in vascular endothelial cells (15, 17), before incubation with AT and stimulation of cells with LPS. As presented in ▷ Figure 4B, the siRNA knockdown of HS 3-OST-1 gene in endothelial cells effectively abrogated the protective activity of AT in response to LPS, suggesting that the interaction of AT with the 3-OS containing HSPGs (HS^{AT↑}) is required for the protective signalling function of the serpin. In agreement with this hypothesis, the optimal concentration of β-AT (AT-N135Q) required to achieve a barrier protective activity in endothelial cells was also significantly reduced (▷ Figure 4C).

Activation of AMPK by AT inhibits the inflammatory JNK signalling during I/R

To explore the intrinsic relationship between AT-mediated activation of AMPK signalling and modulation of proinflammatory responses, we analysed the effect of AT on the induction of both AMPK and JNK signalling pathways in the heart during I/R. There was a strong AMPK activation but no JNK phosphorylation in response to ischaemic stress in the heart (p<0.05), interestingly, we discovered that pretreatment with the AMPK inhibitor, Compound C, which significantly inhibits AMPK phosphorylation induced by ischaemia (p<0.05), markedly elevated JNK phosphorylation in the heart during ischaemia (▷ Figure 5A, upper panel, p<0.05). Moreover, the AMPK kinase dead (KD) heart demonstrated much higher JNK phosphorylation than the wild-type heart (▷ Figure 5B, lower panel, p<0.05) and ischaemic stress further augmented JNK phosphorylation in the AMPK-KD heart (p<0.05 vs AMPK-KD basal, ▷ Figure 5B, lower panel). Consistent with AMPK modulating JNK signalling, mice pretreated with the AMPK specific activator, A769662 (29), attenuated cardiac JNK phosphorylation induced by I/R (▷ Figure 5C, left panel). Likewise, AT-N135Q, which activates AMPK better than AT-WT, exhibited a more effective inhibition of I/R-induced JNK phosphorylation (▷ Figure 5C, right panel). These results indicate that AT-mediated activation of cardiac AMPK down-regulates the JNK inflammatory signalling pathway to protect the heart from damage caused by I/R.

To further explore the mechanism by which activation of AMPK by AT inhibits JNK phosphorylation, we measured the level of 4-hydroxynonenal (4-HNE) which reflects the intracellular oxidative stress status (34–36). The results showed that AT administration significantly inhibits the 4-HNE level caused by I/R (▷ Figure 5D). Intriguingly, AT treatment also augments the AMPK downstream phosphorylation of ULK1, a known modulator of autophagy, which is involved in the elimination of damaged organelles in stressed cells (37) (▷ Figure 5D).

AT modulates glucose and fatty acid oxidation during I/R

One of the most important functions of cardiac AMPK is to increase energy production during stress conditions (24, 25). Activated AMPK can achieve this important physiological process by modulating substrate metabolism through several different mechanisms. AMPK can 1) accelerate fatty acid uptake and oxidation (38), 2) increase glucose uptake (39), and 3) stimulate glycolysis (40). Therefore, the next question was whether the activation of AMPK by AT in the heart modulates substrate metabolism during I/R. Glucose oxidation was measured by the amount of [14C] glucose metabolism into 14CO2 in the ex vivo working hearts (27). Fatty acid oxidation was measured by the incorporation of [9, 10-3H] olate into 3H2O (27). The results showed that AT treatment significantly shifts the increased olate oxidation (▷ Figure 6B and C, p<0.05) in favour of increased glucose oxidation (▷ Figure 6A and C, p<0.05) during I/R, however, it does not affect the rate of glucose and olate oxidation under basal perfusion conditions (▷ Figure 6A, B and C). Moreover, this metabolic-shift function of AT was abolished in the AMPK-KD heart perfusion experiments. Thus, AT did not show a significant effect on the regulation of substrate metabolism in the AMPK-KD hearts during I/R (▷ Figure 6), supporting the hypothesis that AT-mediated AMPK activation exerts a cardioprotective effect through the modulation of energy substrate metabolism during I/R. The cardiac pumping capacity measured in the working heart perfusion system indicated that there is no significant changes in cardiac pumping functions that can be attributed to the AT treatment (Suppl. Table 1, available online at www.thrombosis-online.com).

Discussion

Previous studies have established a protective role for AT in ameliorating myocardial necrosis during I/R injury (9). Results of this study for the first time demonstrate that AT may exert its cardioprotection against I/R injury through activation of AMPK signalling. The activation of AMPK by AT was associated with the inhibition of the pro-inflammatory JNK pathway in the injured heart. Our results further demonstrated that the AMPK-dependent downstream phosphorylation of ACC and eEF2, which are involved in fatty acid oxidation and inhibition of protein synthesis, respectively (24, 29), was enhanced by AT administration in the heart. Metabolic regulation of these pathways by AMPK is expected to save ATP consumption, thereby benefiting the heart’s contractility under I/R stress conditions. We previously demonstrated that AT also inhibits the production of pro-inflammatory cytokines TNF-α, IL-6 and JNK and the activation of the NF-κB pathway by inducing synthesis of PG12 (9, 18). The relationship between the AT elevation of PG12 synthesis and its activation of AMPK in the heart during I/R is not known nor is the extent of the contribution of each one of these pathways to the anti-inflammatory properties of AT.
Ma et al. Cardioprotective function of AT

The results herein, for the first time, showed that AT can inhibit I/R-mediated JNK phosphorylation by the activation of the cardiac AMPK. The in vivo animal experiments showed that AT treatment stimulates cardiac AMPK activation under both physiological and I/R conditions. AMPK has emerged as a key factor in regulating substrate metabolism to protect the stressed heart from I/R injury. In support of this, the attenuation of the induction of cardiac AMPK, by either a pharmacological approach of inhibiting it with Compound C or by a genetic approach of overexpressing the dominant negative catalytic $\alpha_2$ subunit of AMPK in the heart, was associated with elevated I/R-induced pro-inflammatory JNK phosphorylation. On the other hand, the AMPK activator, A-769662, markedly inhibited the stimulation of JNK phosphorylation during I/R. These results further indicate that the activation of cardiac AMPK plays a major anti-inflammatory role in modulating the JNK inflammatory signalling pathway in the I/R-stressed heart. Thus, the anti-inflammatory JNK inhibitory activity of AT during I/R is mediated, at least partially, through the activation of AMPK signalling.

There is evidence that the phosphorylation of the mammalian protein, ULK1, by AMPK is critical for the regulation of autophagy (29, 37). Interestingly, the AT treatment was also associated with augmentation of ULK1 phosphorylation during I/R, indicating that modulation of autophagy by AT may be beneficial since it can provide needed energy to the ischaemic heart through this alternative metabolic pathway. Furthermore, the AT-mediated AMPK activation was associated with the inhibition of 4-HNE modified proteins. 4-HNE is an $\alpha,\beta$-unsaturated hydroxyalkenal that is formed by lipid peroxidation. The elevated level of 4-HNE modified proteins is a good indicator of oxidative stress-mediated reactive oxygen species (ROS) formation, which also appears to be effectively inhibited by AT in the ischaemic heart.

Under normal physiological conditions, fatty acid $\beta$-oxidation is responsible for the major source of energy in the heart, supplying as much as 50–70% of the acetyl CoA-derived ATP. By contrast, glycolysis usually contributes <10% of the overall ATP (24). However, because of insufficient oxygen supply during myocardial ischaemia, glucose becomes the main energy source via glycolysis (25). Increased fatty acid oxidation at the beginning of reperfusion can be associated with a sudden influx of oxygen levels, which may result in increased generation of ROS formation and cardiomyocyte damage (27). An interesting observation of this study was the finding that AT treatment effectively shifted the cardiac substrate metabolism from increased oleate oxidation in

Figure 6: AT treatment augments glucose oxidation and attenuates fatty acid oxidation in the heart during I/R. A-B) Glucose/oleate oxidation in the isolated heart. After balancing 20 min, isolated wild-type (WT) or AMPK KD hearts were subjected to 10 min of ischaemia and 20 min of reperfusion. Glucose oxidation was analysed by measuring $[^{14}\text{C}]$ glucose metabolism into $^{14}\text{CO}_2$. Fatty acid oxidation was measured by the incorporation of $[9, 10-\text{H}]$ oleate into $^{3}\text{H}_2\text{O}$. C) Relative percentage of ATP production from glucose and fatty acid oxidation. Values are means ± SE from three independent experiments for AT treatment, and six independent experiments for control. *p<0.05 vs WT Basal Vehicle or AMPK KD Basal Vehicle, †p<0.05 vs WT I/R Vehicle.
What is known about this topic?
- Antithrombin is a plasma serpin inhibitor that regulates the proteolytic activity of procoagulant proteases of the clotting cascade.
- In addition to its anticoagulant activity, antithrombin also possesses anti-inflammatory properties.
- We have demonstrated that antithrombin exerts a cardioprotective activity against ischaemia/reperfusion injury in a left anterior descending coronary artery (LAD) occlusion model by an unknown mechanism.

What does this paper add?
- This paper demonstrates that antithrombin activates AMP-activated protein kinase in both in vivo and ex vivo conditions in the LAD injury model.
- An antithrombin derivative having high affinity for heparin is more potent AMPK activator and exhibits better cardioprotective activity however a mutant lacking affinity for heparin has no cardioprotective activity and is not capable of activating AMPK.
- Blocking the heparin-binding site of antithrombin by pentasaccharide abrogates the cardioprotective activity of the inhibitor.
- These results suggest that antithrombin binds to heparan sulfate proteoglycans to activate AMPK, thereby protecting the myocardium against post-ischaemic cardiac dysfunction.

favour of increased glucose oxidation during I/R. This metabolic-shift action of AT was mediated through the activation of cardiac AMPK since AT had no metabolic-shift effect on the AMPK KD hearts. The metabolic-shift effect of AT can contribute to its cardioprotective effect by decreasing oleate oxidation, thereby limiting the amount of ROS generation that can cause cardiomyocyte damage during reperfusion. In line with the beneficial effect of accelerated glucose oxidation and decreased fatty acid oxidation in the heart during ischaemia and reperfusion, several fatty acid β-oxidation inhibitors including trimetazidine and ranolazine have emerged as therapeutic drugs which have proven to be effective against ischaemic heart disease (41, 42). Thus, as an AMPK agonist capable of modulating cardiac metabolism, AT may be a therapeutic potential for the treatment of ischaemic heart disease.

Finally, the observation that the AT-4Mut, which cannot interact with heparin, did not activate AMPK suggests that the D-helix dependent interaction of AT with cell surface HSPGs is responsible for the cardioprotective effect of the serpin during I/R. Further support for this hypothesis was provided by the observation that the AT-N135Q mutant, which binds to heparin with higher affinity, activated AMPK with significantly higher potency and exhibited a significantly higher cardioprotective activity (Figure 3B). Furthermore, the high-affinity AT-binding pentasaccharide inhibited the AMPK activating property of the serpin. These results suggest that the signalling activity, but not the anticoagulant activity of AT, is solely responsible for the AMPK-dependent cardioprotective activity of AT. Previous studies have indicated that AT interaction with a small fraction of vascular HSPGs that contain 3-O-sulfate modification (HS\textsuperscript{AT⁺}) may be responsible for the anti-inflammatory signalling activity of the serpin. In support of this hypothesis, it has been demonstrated that the knockout mutant of mice lacking the enzyme responsible for the synthesis of 3-OS (HS 3-OST-1) exhibit normal haemostatic function; however, they show a proinflammatory phenotype and, unlike wild-type mice, they do not respond to AT if challenged with LPS (15). The observation of this study that the siRNA knockdown of HS 3-OST-1 abrogated the signalling function of AT in the LPS-stimulated endothelial cells supports the hypothesis that the interaction of AT with 3-OS containing HSPGs may be responsible for the AMPK-dependent protective activity of the serpin. Thus, the AT-N135Q mutant warrants further investigation for its therapeutic potential in preventing cardiac I/R injury.

Acknowledgements
We would like to thank Audrey Rezaie for proofreading the manuscript. This work was supported by grants from NIH HL62526 and HL101917, the American Heart Association (12GRNT11620029 and 14IRG18290014), National Natural Science Foundation of China (No. 31171121), and the American Diabetes Association (1–11-BS-92 and 1–14-BS-131).

Conflicts of interest
None declared.

References


